Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following ...

SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...

MIRA Pharmaceuticals has completed dosing in its Phase I clinical trial of Ketamir-2, the company’s selective oral N-methyl-D-aspartate (NMDA) receptor modulator, assessing its safety, tolerability, ...

Scientists have long searched for ways to treat Alzheimer’s disease, the most common form of dementia. Chief among these ...

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of around 20% during the forecast period. This rapid expansion is primarily fueled by the rising prevalence of ...

For over thirty years, researchers have primarily studied the accumulation of amyloid beta proteins in the brains of Alzheimer’s patients. They also focus on how that component negatively impacts ...

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and ...

研究人员首次直接捕捉到氯胺酮如何改变难治性抑郁症（Treatment-Resistant Depression, TRD）患者大脑中的关键受体的图像。这种区域特异性的变化与症状的改善密切相关，为快速起效的抗抑郁药的作用机制提供了新的见解。（背景延伸：氯胺酮是一种NMDA受体拮抗剂，最初用作麻醉剂，后来发现其具有快速抗抑郁效果。与传统抗抑郁药需要数周才能起效不同，氯胺酮通常在数小时内即可缓解抑郁症状 ...

Alzheimer disease (AD) is the most common cause of dementia and one of the leading causes of death in adults age 65 y or ...